SCHEMBL441220

SCHEMBL441220

CCOC(=O)C(=O)CCCc1ccc2cc(OC)ccc2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.59
LMNA P02545 3/20 0.59
CYP1A2 P05177 2/20 0.59
NPC1 O15118 2/20 0.59
RAB9A P51151 2/20 0.59
MAPT P10636 2/20 0.59
TP53 P04637 1/20 0.59
CYP3A4 P08684 1/20 0.59
MAOA P21397 1/20 0.59
SLC6A2 P23975 1/20 0.59
SLC6A3 Q01959 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
PTGS1 P23219 1/20 0.51
AKR1C3 P42330 1/20 0.51
AKR1C2 P52895 1/20 0.51
ALOX5 P09917 2/20 0.49
PTGS2 P35354 1/20 0.49
HCAR2 Q8TDS4 1/20 0.46
PLAAT3 P53816 1/20 0.44
PLAAT5 Q96KN8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15932043 0.91 LMNA (0.53) KDM4ELMNACYP1A2NPC1RAB9A
SCHEMBL7641739 0.89 ALOX5 (0.61) ALOX5PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL7642001 0.85 MTNR1A (0.56) MTNR1A
SCHEMBL3692545 0.83 CYP1A2 (0.66) KDM4ELMNACYP1A2NPC1RAB9A
SCHEMBL12946405 0.82 MAPT (0.68) KDM4ELMNACYP1A2NPC1RAB9A
SCHEMBL20020280 0.82 CYP1A2 (0.64) KDM4ELMNACYP1A2NPC1RAB9A
SCHEMBL15802556 0.81 CYP1A2 (0.68) KDM4ELMNACYP1A2NPC1RAB9A
SCHEMBL17288829 0.81 CYP1A2 (0.82) KDM4ELMNACYP1A2NPC1RAB9A
SCHEMBL7060212 0.80 F2RL1 (0.58) LMNANPC1RAB9AMAPTALOX5
SCHEMBL7061931 0.79 CYP1A2 (0.51) KDM4ELMNACYP1A2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065179-A1 PRODRUG COMPRISING BETA-KETO CARBOXYLIC ACID, BETA-KETO CARBOXYLIC ACID SALT OR BETA-KETO CARBOXYLIC ACID ESTER FOR DRUG DELIVERY YKI, Ytemiska Institutet AB (SE) 2012-03-15 US disclosed
EP-2419398-A1 A PRODRUG COMPRISING BETA-KETO CARBOXYLIC ACID, BETA-KETO CARBOXYLIC ACID SALT OR BETA-KETO CARBOXYLIC ACID ESTER FOR DRUG DELIVERY YKI, Ytkemiska Institutet AB (SE) 2012-02-22 EP disclosed
WO-2010120232-A1 A PRODRUG COMPRISING BETA-KETO CARBOXYLIC ACID, BETA-KETO CARBOXYLIC ACID SALT OR BETA-KETO CARBOXYLIC ACID ESTER FOR DRUG DELIVERY YKI, YTKEMISKA INSTITUTET AB (SE) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065179-A1 PRODRUG COMPRISING BETA-KETO CARBOXYLIC ACID, BETA-KETO CARBOXYLIC ACID SALT OR BETA-KETO CARBOXYLIC ACID ESTER FOR DRUG DELIVERY BCKDK, KHK, CA7 KDM4E 904/4885LMNA 1615/4885CYP1A2 1709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.